# myeloMATCH

Source: https://onco.cc/trials/myelomatch/  
OnCo record `myelomatch` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

myeloMATCH is a US-wide master trial that sequences every new leukaemia within days and routes the patient to the right experimental arm, then re-routes them as MRD results come in.

## Summary

Launched 2024 across ~200 sites. Rapid central genomics (results in 72 hours) and MRD assessments at each 'tier' allow patients to move between sub-studies (e.g., FLT3, TP53, NPM1, older-unfit cohorts) testing venetoclax, menin inhibitors, FLT3 inhibitors, magrolimab successors, and CPX-351. The infrastructure model for precision leukaemia trials.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-07
- Registry id: NCT05564390
- Phase: platform
- Setting: Newly diagnosed AML and MDS: genomic screening at diagnosis assigns patients to tiered, biomarker-defined sub-studies from induction through MRD-guided consolidation and maintenance
- Sponsor: NCI / National Clinical Trials Network

## Sources

- ClinicalTrials.gov NCT05564390: https://clinicaltrials.gov/study/NCT05564390

## Connected records

- cancers: [Acute myeloid leukaemia](https://onco.cc/cancers/aml/), [Acute myeloid leukaemia in older or unfit patients](https://onco.cc/cancers/aml-older-unfit/), [FLT3-mutated acute myeloid leukaemia](https://onco.cc/cancers/aml-flt3/), [IDH1- and IDH2-mutated acute myeloid leukaemia](https://onco.cc/cancers/aml-idh/), [NPM1-mutated and KMT2A-rearranged acute myeloid leukaemia](https://onco.cc/cancers/aml-npm1-kmt2a/), [Secondary and therapy-related acute myeloid leukaemia](https://onco.cc/cancers/aml-secondary/)
- technologies: [Comprehensive genomic profiling](https://onco.cc/technologies/cgp/), [NGS-based MRD (clonoSEQ and molecular MRD)](https://onco.cc/technologies/ngs-mrd-clonoseq/)
- drugs: [CPX-351 (liposomal daunorubicin-cytarabine)](https://onco.cc/drugs/cpx-351/), [Venetoclax](https://onco.cc/drugs/venetoclax/), [Ziftomenib](https://onco.cc/drugs/ziftomenib/)
- institutions: [National Cancer Institute (NIH)](https://onco.cc/institutions/nci/)
- terms: [Basket, umbrella, and platform trials](https://onco.cc/terms/basket-umbrella-platform/), [Master protocol (platform, basket and umbrella trials)](https://onco.cc/terms/master-protocol/), [MRD-negative complete remission](https://onco.cc/terms/mrd-negative-cr/), [Response-adaptive randomisation](https://onco.cc/terms/response-adaptive-randomisation/), [Seamless, adaptive and Bayesian trial designs](https://onco.cc/terms/seamless-adaptive/), [Umbrella trial](https://onco.cc/terms/umbrella-trial/)
- ideas: [MRD-guided transplant decisions in intermediate-risk AML](https://onco.cc/ideas/idea-mrd-guided-transplant-aml/)
- bottlenecks: [Too many combinations to test](https://onco.cc/bottlenecks/b-combination-space/), [Trial design, endpoints and cost](https://onco.cc/bottlenecks/b-trial-design/)
- trials: [Beat AML Master Trial](https://onco.cc/trials/beat-aml-master-trial/), [NCI-MATCH (EAY131)](https://onco.cc/trials/nci-match/)

---
JSON: https://onco.cc/api/v1/entities/myelomatch.json